Moreover, when GLP-1based medications are administered, they also stimulate peripheral GLP-1 receptors on vagal nerve fibers that carry sensory information from the stomach and intestines to the brainstem
Discussion While GLP-1 RAs are powerful anti-obesity medications (AOMs), they do raise some serious concerns most notably, up to 40% of the profound weight loss induced by these agents can be due to loss of lean mass 3,4,5 and prior studies have shown that a significant portion of this lean mass is muscle 33,34,35
Clinical documents : ER records, imaging or tests (HIDA scan, CT for obstruction, gastric-emptying studies), operative and pathology reports
[PubMed] Yoneda M, Yamamoto T, Honda Y, Imajo K, Ogawa Y, Kessoku T, Kobayashi T, Nogami A, Higurashi T, Kato S, Hosono K, Saito S, Nakajima A (2021) Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: A retrospective nationwide claims database study in Japan
Consultation required to determine eligibility
